OctreoPharm Sciences

Ipsen announced the signature of an agreement to acquire OctreoPharm Sciences, a private German life sciences company developing innovative radioactive-labeled compounds for molecular imaging diagnostics and therapeutic applications. Ipsen plans to maintain the company location and staff to ensure successful transition of know-how and expertise. The company expects to complete its acquisition once closing conditions have been cleared.